Table 1.
Baseline patient characteristics upon the initial diagnosis of Crohn’s disease.
| MTX Group | AZA Group | p-Value | ||
|---|---|---|---|---|
| Patients (n) | 15 | 14 | ||
| Age (years) | 13.48 (11.61–15.36) | 13.16 (11.13–15.20) | 0.770 a | |
| Male sex (%) | 14 (93.3%) | 11 (78.6%) | 0.331 b | |
| BMI | 19.46 (17.38–21.55) | 19.09 (17.43–20.75) | 0.496 a | |
| Hematocrit (%) | 42.05 (4013–43.95) | 39.73 (38.02–41.44) | 0.065 a | |
| Albumin (g/dL) | 4.43 (4.5–4.1) | 4.33 (4.20–4.47) | 0.237 a | |
| ESR (mm/hr) | 9.47 (3.13–15.81) | 17.42 (9.52–25.32) | 0.095 a | |
| CRP (mg/dL) | 0.27 (0.11–0.43) | 0.56 (0.19–0.92) | 0.130 a | |
| Calprotectin (mg/kg) | 1440.73 (723.87–2157.59) |
1616.97 (1089.97–2143.97) |
0.529 a | |
| PCDAI c | 30.38 (28.73–32.03) | 31.54 (30.36–32.72) | 0.244 a | |
| Initial dose of the drug | 14.66 mg/BSA (14.13–15.2) |
0.53 mg/kg (0.49–0.56) |
||
| Dosage of the drugs at 54 weeks | 12.26 mg/BSA (10.01–14.43) |
0.66 mg/kg (0.57–0.76) |
||
| Dose of mesalazine (mg/kg) | 46.08 (41.4–50.76) | 43.93 (39.57–48.28) | 0.210 a | |
| TPMT mutations (patient number) | 1 (6.7) | 1 (7.1) | ||
| NUDT15 mutations (patient number) | 2 (13.3) | 4 (28.6) | ||
| Paris classification at diagnosis | ||||
| Age at diagnosis | A1a | 2 (13.3) | 4 (28.6) | |
| A1b | 11 (73.3) | 5 (35.7) | ||
| A2 | 2 (13.3) | 5 (35.7) | ||
| Location | L1 | 2 (13.3) | 1 (7.1) | |
| L2 | 1 (6.7) | 1 (7.1) | ||
| L3 | 13 (86.7) | 12 (85.7) | ||
| L4a | 6 (40) | 3 (21.4) | ||
| L4b | 2 (13.3) | 4 (28.6) | ||
| L4ab | 7 (46.7) | 7 (50) | ||
| Behavior | B1 | 15 (100) | 14 (100) | |
| B2 | 0 | 0 | ||
| B3 | 0 | 0 | ||
| p | 13 (86.7) | 10 (71.4) | ||
Values are presented as median (interquartile range) or number (%). a: independent-sample t-test, b: Mann–Whitney U test, c: Pediatric Crohn’s Disease Activity Index (PCDAI) score ranging from 0 to 100, with higher scores indicating more active disease. A score <10 indicates inactive disease, 11–30 indicates mild disease, and >30 indicates moderate-to-severe disease. BMI, body-mass index; ESR, erythrocyte-sedimentation rate; CRP, C-reactive protein; PCDAI, Pediatric Crohn’s Disease Activity Index; TPMT, thiopurine methyltransferase; NUDT15, nudix hydrolase 15. The classification in the table is as follows. A1a: age <10 years, A1b: 10 to <17 years, A2: age ≥ 17 years, L1: distal 1/3 ileum ±limited cecal disease, L2: colonic disease, L3: ileocolonic disease, L4a: upper disease proximal to ligament of Treitz, L4b: upper disease distal to the ligament of Treitz and proximal to the distal 1/3 ileum, L4ab: upper disease involvement in both L4a and Lab. B1: non-stricturing, non-penetrating behavior, B2: stricturing behavior, B3: penetrating behavior, P: perianal disease modifier.